Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.04
QDEL's Cash to Debt is ranked lower than
62% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.23 vs. QDEL: 1.04 )
Ranked among companies with meaningful Cash to Debt only.
QDEL' s Cash to Debt Range Over the Past 10 Years
Min: 0.09  Med: 2.01 Max: N/A
Current: 1.04
Equity to Asset 0.52
QDEL's Equity to Asset is ranked lower than
63% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. QDEL: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
QDEL' s Equity to Asset Range Over the Past 10 Years
Min: 0.52  Med: 0.79 Max: 0.88
Current: 0.52
0.52
0.88
F-Score: 4
Z-Score: 3.09
M-Score: -2.88
WACC vs ROIC
9.22%
-1.85%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -4.02
QDEL's Operating margin (%) is ranked lower than
52% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.98 vs. QDEL: -4.02 )
Ranked among companies with meaningful Operating margin (%) only.
QDEL' s Operating margin (%) Range Over the Past 10 Years
Min: -13.49  Med: 7.44 Max: 31.99
Current: -4.02
-13.49
31.99
Net-margin (%) -6.40
QDEL's Net-margin (%) is ranked lower than
52% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.56 vs. QDEL: -6.40 )
Ranked among companies with meaningful Net-margin (%) only.
QDEL' s Net-margin (%) Range Over the Past 10 Years
Min: -9.94  Med: 4.49 Max: 20.49
Current: -6.4
-9.94
20.49
ROE (%) -5.96
QDEL's ROE (%) is ranked lower than
51% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.35 vs. QDEL: -5.96 )
Ranked among companies with meaningful ROE (%) only.
QDEL' s ROE (%) Range Over the Past 10 Years
Min: -9.43  Med: 4.31 Max: 26.77
Current: -5.96
-9.43
26.77
ROA (%) -3.14
QDEL's ROA (%) is ranked higher than
54% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.02 vs. QDEL: -3.14 )
Ranked among companies with meaningful ROA (%) only.
QDEL' s ROA (%) Range Over the Past 10 Years
Min: -5.92  Med: 2.99 Max: 21.27
Current: -3.14
-5.92
21.27
ROC (Joel Greenblatt) (%) -9.85
QDEL's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -8.16 vs. QDEL: -9.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
QDEL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -33.25  Med: 21.44 Max: 145.36
Current: -9.85
-33.25
145.36
Revenue Growth (3Y)(%) 7.60
QDEL's Revenue Growth (3Y)(%) is ranked higher than
66% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.70 vs. QDEL: 7.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
QDEL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -5.1  Med: 6.6 Max: 20.5
Current: 7.6
-5.1
20.5
EBITDA Growth (3Y)(%) -7.80
QDEL's EBITDA Growth (3Y)(%) is ranked lower than
67% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. QDEL: -7.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
QDEL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -58.5  Med: 3.9 Max: 245.9
Current: -7.8
-58.5
245.9
GuruFocus has detected 1 Warning Sign with Quidel Corp $QDEL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» QDEL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

QDEL Guru Trades in Q4 2015

Jim Simons 207,687 sh (+124.04%)
Mario Gabelli 600,000 sh (unchged)
Joel Greenblatt Sold Out
» More
Q1 2016

QDEL Guru Trades in Q1 2016

Jim Simons 300,500 sh (+44.69%)
Mario Gabelli 624,100 sh (+4.02%)
» More
Q2 2016

QDEL Guru Trades in Q2 2016

Jim Simons 404,700 sh (+34.68%)
Mario Gabelli 626,100 sh (+0.32%)
» More
Q3 2016

QDEL Guru Trades in Q3 2016

Jim Simons 484,300 sh (+19.67%)
Mario Gabelli 626,100 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with QDEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:NYSE:ARA, NAS:NEO, NAS:FMI, NAS:NTRA, NAS:BEAT, NAS:VIVO, NAS:NRCIA, NAS:HSKA, NAS:ONVO, NAS:NVDQ, NYSE:NVTA, NAS:SRDX, NYSE:ENZ, NAS:GHDX, NAS:LNTH, NAS:OXFD, NAS:RDNT, NAS:ALOG, AMEX:SENS, NAS:FLGT » details
Traded in other countries:QL1.Germany,
Quidel Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. It includes applications in infectious diseases, women's health and gastrointestinal diseases.

Quidel Corp is a corporation, originally incorporated as Monoclonal Antibodies, Inc. in California in 1979 and re-incorporated as Quidel Corporation in the State of Delaware in 1987. The Company is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. These diagnostic testing solutions include applications in infectious diseases, women's health and gastrointestinal diseases. It sells products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. It markets its products in the United States through a network of national and regional distributors, and through a direct sales force. Internationally, it markets through distributor arrangements. The Company commenced its operations in 1979 and launched its first products, dipstick-based pregnancy tests, in 1983. In February 2010, it expanded its operations through the acquisition of Diagnostic Hybrids, Inc., a privately-held, in vitro diagnostics (IVD) company, based in Athens, Ohio. In 2013, it completed two further acquisitions, acquiring BioHelix Corporation, a developer and manufacturer of isothermal molecular assays and enzymes, in May 2013, and acquiring the assets of AnDiaTec GmbH, a German based developer and manufacturer of molecular assays, in August 2013. The Company's customers for IVD products are centralized laboratories and physician offices and decentralized point-of-care settings. It provides diagnostic testing solutions under various brand names, including, among others, - Quidel, QuickVue, QuickVue+, Sofia, AmpliVue, Solana, Virena, MicroVue, Lyra, FreshCells, D3, FastPoint, ReadyCells, Super E-Mix, ELVIRA, ELVIS and Thyretain. The diagnostic testing solutions are provided through a number of proprietary platforms, including Fluorescent Immunoassays; Molecular Assays; Molecular Systems in Development; and Connectivity and Data Management. The products under medical and wellness categories are Infectious Diseases - Influenza, Streptococci, RSV, Multiplex Respiratory, General Virology, Herpes and Herpes Family; POC Women's and General Health - Pregnancy, Graves Disease, Chlamydia, Bone Health; Bone Health, Autoimmune Disease and Oncology; Gastrointestinal Diseases - Clostridium difficile, Enterovirus, Helicobacter pylori, Immunoassay fecal occult blood. The Company has two manufacturing sites in San Diego, California and Athens, Ohio. San Diego facility consists of laboratories devoted to tissue culture, cell culture, protein purification and immunochemistry and production areas dedicated to manufacturing and assembly. Athens facility consists of clean rooms (FS-209E Class 1000: ISO Class 6) for the culturing and dispensing of cell cultures under cGMP conditions. The facility also has laboratories devoted to tissue culture for the production of monoclonal an

Top Ranked Articles about Quidel Corp

Douglas Bryant Sells Quidel Corp The CEO and president sold 69,168 shares
Douglas Bryant (Insider Trades), CEO and president of Quidel Corp. (NASDAQ:QDEL), sold 69,168 shares of the company on Sept. 30. The average price per share was $21.76, for a total transaction of $1,505,096. Quidel, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, has a market cap of $704.21 million. Read more...

Ratios

vs
industry
vs
history
Forward P/E 34.36
QDEL's Forward P/E is ranked lower than
70% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.57 vs. QDEL: 34.36 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.31
QDEL's P/B is ranked higher than
59% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.72 vs. QDEL: 3.31 )
Ranked among companies with meaningful P/B only.
QDEL' s P/B Range Over the Past 10 Years
Min: 2.12  Med: 3.54 Max: 6.72
Current: 3.31
2.12
6.72
P/S 3.44
QDEL's P/S is ranked higher than
50% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.44 vs. QDEL: 3.44 )
Ranked among companies with meaningful P/S only.
QDEL' s P/S Range Over the Past 10 Years
Min: 1.84  Med: 3.92 Max: 6.17
Current: 3.44
1.84
6.17
POCF 61.32
QDEL's POCF is ranked lower than
90% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.37 vs. QDEL: 61.32 )
Ranked among companies with meaningful POCF only.
QDEL' s POCF Range Over the Past 10 Years
Min: 5.39  Med: 20.05 Max: 75.1
Current: 61.32
5.39
75.1
EV-to-EBITDA 42.98
QDEL's EV-to-EBITDA is ranked lower than
87% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.79 vs. QDEL: 42.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
QDEL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -176.9  Med: 18.6 Max: 189.5
Current: 42.98
-176.9
189.5
Shiller P/E 80.80
QDEL's Shiller P/E is ranked lower than
86% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 40.31 vs. QDEL: 80.80 )
Ranked among companies with meaningful Shiller P/E only.
QDEL' s Shiller P/E Range Over the Past 10 Years
Min: 37.84  Med: 72.89 Max: 167.33
Current: 80.8
37.84
167.33
Current Ratio 8.23
QDEL's Current Ratio is ranked higher than
91% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.59 vs. QDEL: 8.23 )
Ranked among companies with meaningful Current Ratio only.
QDEL' s Current Ratio Range Over the Past 10 Years
Min: 1.64  Med: 4.34 Max: 8.6
Current: 8.23
1.64
8.6
Quick Ratio 7.31
QDEL's Quick Ratio is ranked higher than
91% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. QDEL: 7.31 )
Ranked among companies with meaningful Quick Ratio only.
QDEL' s Quick Ratio Range Over the Past 10 Years
Min: 1.12  Med: 3.36 Max: 7.6
Current: 7.31
1.12
7.6
Days Inventory 123.26
QDEL's Days Inventory is ranked lower than
62% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 85.13 vs. QDEL: 123.26 )
Ranked among companies with meaningful Days Inventory only.
QDEL' s Days Inventory Range Over the Past 10 Years
Min: 73.81  Med: 90.85 Max: 130.22
Current: 123.26
73.81
130.22
Days Sales Outstanding 50.00
QDEL's Days Sales Outstanding is ranked higher than
68% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. QDEL: 50.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
QDEL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 21.59  Med: 62.03 Max: 76.33
Current: 50
21.59
76.33
Days Payable 56.93
QDEL's Days Payable is ranked lower than
52% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.33 vs. QDEL: 56.93 )
Ranked among companies with meaningful Days Payable only.
QDEL' s Days Payable Range Over the Past 10 Years
Min: 29.04  Med: 36.17 Max: 61.12
Current: 56.93
29.04
61.12

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.10
QDEL's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.50 vs. QDEL: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
QDEL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6.6  Med: -3.3 Max: 4.7
Current: 0.1
-6.6
4.7

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 22.65
QDEL's Price/Net Current Asset Value is ranked lower than
81% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.71 vs. QDEL: 22.65 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
QDEL' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.45  Med: 11.6 Max: 272.83
Current: 22.65
3.45
272.83
Price/Tangible Book 7.72
QDEL's Price/Tangible Book is ranked lower than
63% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. QDEL: 7.72 )
Ranked among companies with meaningful Price/Tangible Book only.
QDEL' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.15  Med: 4.98 Max: 15.49
Current: 7.72
1.15
15.49
Price/Projected FCF 2.74
QDEL's Price/Projected FCF is ranked lower than
62% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.02 vs. QDEL: 2.74 )
Ranked among companies with meaningful Price/Projected FCF only.
QDEL' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.98  Med: 2.55 Max: 11.48
Current: 2.74
0.98
11.48
Price/Median PS Value 0.88
QDEL's Price/Median PS Value is ranked higher than
63% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. QDEL: 0.88 )
Ranked among companies with meaningful Price/Median PS Value only.
QDEL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 0.8 Max: 1.53
Current: 0.88
0.26
1.53
Earnings Yield (Greenblatt) (%) -1.10
QDEL's Earnings Yield (Greenblatt) (%) is ranked higher than
50% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.90 vs. QDEL: -1.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
QDEL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.1  Med: 3.6 Max: 17.3
Current: -1.1
-1.1
17.3
Forward Rate of Return (Yacktman) (%) -9.01
QDEL's Forward Rate of Return (Yacktman) (%) is ranked lower than
86% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.51 vs. QDEL: -9.01 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
QDEL' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -9.1  Med: 2.4 Max: 49.7
Current: -9.01
-9.1
49.7

More Statistics

Revenue (TTM) (Mil) $191.2
EPS (TTM) $ -0.38
Beta1.19
Short Percentage of Float19.65%
52-Week Range $13.21 - 23.94
Shares Outstanding (Mil)32.64

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 203 229
EPS ($) 0.32 0.58
EPS w/o NRI ($) 0.32 0.58
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for QDEL

Headlines

Articles On GuruFocus.com
Douglas Bryant Sells Quidel Corp. Oct 03 2016 
Top Insider Buys Highlight: Quidel Corporation Jul 28 2014 
Weekly CEO Buys Highlight: TDY, KOPN, QDEL, SALM, FCAL Mar 24 2012 
CEO Buys 6/10/11: Quidel Corp. Jun 10 2011 
Quidel Corp. Reports Operating Results (10-Q) Oct 29 2010 
Quidel Corp. Reports Operating Results (10-Q) Jul 30 2010 
Quidel Corp. (QDEL) CFO John Matthew Radak buys 1,000 Shares Jun 22 2010 
Quidel Corp. Reports Operating Results (10-Q) May 03 2010 
MFI STOCK REVIEW: QUIDEL CORP (QDEL) Apr 01 2010 
Take Advantage of a 43% Upside on this Healthcare Reform Stock Trade Mar 30 2010 

More From Other Websites
Quidel Announces Preliminary Revenue for Fourth Quarter 2016 Jan 06 2017
QUIDEL CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jan 06 2017
Quidel Announces Preliminary Revenue for Fourth Quarter 2016 Jan 06 2017
Quidel to Present at 35th Annual J.P. Morgan Healthcare Conference Dec 20 2016
Quidel Corp. – Value Analysis (NASDAQ:QDEL) : December 20, 2016 Dec 20 2016
Quidel Corp. breached its 50 day moving average in a Bearish Manner : QDEL-US : December 19, 2016 Dec 19 2016
Quidel downgraded by Piper Jaffray Dec 16 2016
ETFs with exposure to Quidel Corp. : December 13, 2016 Dec 13 2016
Should You Add Corcept Therapeutics Incorporated (CORT) To Your Portfolio? Dec 10 2016
QUIDEL CORP /DE/ Files SEC form 8-K, Termination of a Material Definitive Agreement Dec 02 2016
ETFs with exposure to Quidel Corp. : November 30, 2016 Nov 30 2016
Quidel Receives FDA Clearance for Its New Solana(R) Molecular Assay for the Detection of Herpes... Nov 29 2016
Quidel to Present at the 28th Annual Piper Jaffray Healthcare Conference Nov 17 2016
QUIDEL CORP /DE/ Financials Nov 03 2016
ETF’s with exposure to Quidel Corp. : November 2, 2016 Nov 02 2016
Quidel Corp. :QDEL-US: Earnings Analysis: Q3, 2016 By the Numbers : October 31, 2016 Oct 31 2016
QUIDEL CORP /DE/ Files SEC form 10-Q, Quarterly Report Oct 28 2016
Thermo Fisher (TMO) Tops Q3 Earnings, Raises '16 Outlook Oct 27 2016
NuVasive (NUVA) Earnings & Revenues Miss Estimates in Q3 Oct 27 2016
Abaxis (ABAX) Q2 Earnings & Revenues Miss, Margins Slide Oct 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)